Login to get immediate access to this content.
LoginLearning objectives
- To understand the best standard approach for patients with localised oesophageal cancer
- To select the optimal sequence of Immune Checkpoint Inhibitors when treating advanced oesophageal cancer
- To properly use different predictive biomarkers to get the maximum benefit of Immune Checkpoint Inhibitors